Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
Australia’s regulatory agency rejected Biogen and Eisai’s Alzheimer’s drug Leqembi, noting that the drug's efficacy doesn't ...
In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...
While Alzheimer’s can’t be reversed, Leqembi has proven that it can slow down the progression of the disease.
The Therapeutic Goods Administration (TGA) has made the decision not to register lecanemab (LEQEMBI) for the treatment of ...
The Food and Drug Administration endorsed the IV drug, Leqembi, for patients with mild dementia and other symptoms caused by early Alzheimer’s disease. It’s the first medicine that’s been ...
When Dennis Carr learned he had early Alzheimer’s disease, he immediately thought of his older brother who had died of the illness in 2023. “There was not much anyone could do,” Carr said of ...
The earlier MCI due to AD and mild AD dementia are diagnosed and treated, the greater the opportunity for benefit [1] Last July, the U.S. Food and Drug Administration (FDA) issued a notable ...
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback